Compiled all in one place, read news articles from each of the news categories, about drugs, the pharmaceutical industry, national and international awareness causes, scientific meetings, trending stories and epgonline.org headlines.

Site News

Added 23 hours ago Drug news

European Commission approves Orkambi for the treatment of children with cystic fibrosis aged 2 to 5 years old who have two copies of the F508del mutation. - Vertex Pharma

Vertex Pharmaceuticals (Europe) Limited announced that the European Commission has granted approval of the label extension for Orkambi (lumacaftor/ivacaftor) for...

Added 2 days ago Drug news

Phase III trial of Imbruvica + chemo fails to meet endpoint in pancreatic cancer.- AbbVie

AbbVie announced an update on the Phase III RESOLVE trial (PCYC-1137) of Imbruvica (ibrutinib) in combination with chemotherapy agents nab-paclitaxel...

Added 2 days ago Drug news

Phase III REACH-2 study of Cyramza to treat AFP-High liver cancer is published in The Lancet Oncology. - Eli Lilly

Eli Lilly and Company announced that results from the global Phase III REACH-2 study of Cyramza (ramucirumab) as a single...

Added 2 days ago Drug news

FDA Advisory Committee recommends Evenity to treat osteoporosis- Amgen + UCB

Amgen and UCB announced strong support from the FDA Bone, Reproductive and Urologic Drugs Advisory Committee (BRUDAC) for the approval...

Added 2 days ago Drug news

UK NICE recommends use of Verzenios in breast cancer.- Eli Lilly

The UK's NICE has recommended the use of Verzenios (abemaciclib), from Eli Lilly, for locally advanced or metastatic forms of...

Added 3 days ago Drug news

NICE recommends Venclyxto plus Rituxan in chronic lymphocytic leukaemia.- AbbVie + Genentech/Roche

The National Institute for Health and Care Excellence (NICE) has recommended Venclyxto (venetoclax) with Rituxan (rituximab), from AbbVie + Genentech/Roche,...

Added 3 days ago Drug news

Complete Response Letter for sacituzumab govitecan for the treatment of patients with metastatic triple-negative breast cancer . Immunomedics

Immunomedics, Inc. announced it has received a Complete Response Letter (CRL) from the FDA for the Biologics License Application (BLA)...

Added 3 days ago Drug news

NICE recommends Bravtovi + Mektovi combination in melanoma.- Pierre Fabre + Array Biopharma

The UK National Institute for Health and Care Excellence (NICE) has recommended Bravtovi (encorafenib) plus Mektovi (binimetinib) from Pierre Fabre...

Added 3 days ago Drug news

FDA advisory committee voted 8:8 on the overall benefits of Zynquista to treat type 1 diabetes. Sanofi + Lexicon

The Endocrinologic and Metabolic Drugs Advisory Committee of the FDA voted eight to eight on the question of whether the...

Added 3 days ago Drug news

Three post approval studies of sutureless Perceval Aortic Heart Valve.-LivaNova PLC

LivaNova PLC announced the publication of three separate studies highlighting the unique performance of its sutureless aortic valve, Perceval. The...

Search all news articles